Connect with us

Politics

Top Democratic Senator Calls Medical Marijuana A ‘Laughing Matter’

Published

on

A top-ranking Democratic senator called into question the therapeutic value of marijuana on Tuesday while also making a broader point about how the federal drug classification system inhibits medical research.

Sen. Dick Durbin (D-IL) made the comments during a Senate Judiciary Committee hearing on the opioid epidemic and federal moves to restrict powerful fentanyl analogues.

Before getting into his views on the potential consequences of permanently placing those opioids in Schedule I of the Controlled Substances Act (CSA), Durbin, the Senate Democratic whip, took a hit at medical cannabis.

“My state just decided in the last few days to make marijuana legal in my state for recreational purposes, starting January 1,” he said, referencing the passage of a cannabis legalization bill through the Illinois legislature last week. “We’ve had medical marijuana. I’ve been to one of those clinics. It was almost a laughing matter.”

“The medical claims they make about marijuana go way beyond anything that’s been proven,” he said. “There are no clinical trials going on.”

Watch Durbin’s medical cannabis comments around 1:00:00 into the video below:

 

Durbin’s views on medical cannabis and marijuana reform in general are at odds with those expressed by many of his Democratic colleagues—not to mention a majority of voters. He said earlier this year that he opposed criminalizing cannabis use, but he cautioned against the other “extreme” of legalizing the plant.

Legalization advocates took issue with Durbin’s characterization of medical cannabis.

“Senator Durbin’s comments surrounding the efficacy and therapeutic benefits of cannabis are ignorant at best and cruel at worst,” Justin Strekal, political director of NORML, told Marijuana Moment. “There are over 30,000 peer-reviewed studies hosted on pubmed.gov on the effects of cannabis, including many showing declines in cases of opioid abuse and overdose fatalities.”

“If Mr. Durbin is serious about addressing the opioid crisis, then he ought not to disparage the role or lives saved that legal marijuana can play,” Stekal said.

Michael Liszewski, principal of The Enact Group, a lobbying and consulting firm that focuses on cannabis, told Marijuana Moment he agrees that the “Schedule I status has prevented more robust medical cannabis research,” but that “it’s disappointing that Senator Durbin is characterizing it as a ‘laughing matter.'”

“To imply that patients need to look sick enough in order to obtain relief from medical cannabis ignores at least two points: First, many ailments that are treated by medical cannabis are not readily visible to observers, such as Crohn’s, lupus, and PTSD (all of which are qualifying conditions in Illinois). And second, it ignores the very real possibility that these individuals look healthy because their medical cannabis therapy is providing them with benefit.”

David Mangone, director of government affairs and counsel at Americans for Safe Access, also criticized the lawmaker’s remarks.

“Senator Durbin’s comments about the medical cannabis program in Illinois are an insult to the thousands of people in his state’s program who use cannabis as a life-saving medicine,” he told Marijuana moment.

“Ignoring the fact that there are nearly 400 [National Institutes of Health] supervised clinical trials on cannabis either underway or recruiting participants, and comparing cannabis to fentanyl analogues, is disingenuous, ill-informed, and dangerous for public policy,” Mangone said.

While the senator was dismissive of medical cannabis at the hearing, arguing that we “are not establishing whether marijuana is in fact medically appropriate in so many circumstances where they claim they are,” he also said that the Schedule I status of cannabis is the reason, in his view, that evidence about its therapeutic benefits of cannabis is insufficient.

“Why don’t they [research cannabis]? Because we’ve moved marijuana to Schedule I—the same place we’re about to move all fentanyl analogues,” he said.

“Under a blanket Schedule I framework, which is being asked for today, we could imperil research into more powerful naloxone—a stronger and better treatment to save lives of those who have used fentanyl analogues,” he added. “Is that what we want to do? I don’t think so.”

Liszewski said there “simply was no need for the senator to slander medical cannabis therapy while making his valid point about how Schedule I status harms medical research.”

Durbin later questioned the Drug Enforcement Administration’s opioid production quota, stating that there’s no need to manufacture such a high volume of prescription painkillers. In one of his closing remarks, he made a play on a Reagan-era anti-drug message.

It’s time to say no,” he said. “Just say no—to pharma when they want that kind of production.”

Though the senator made his thoughts on the scheduling system clear, he’s so far declined to sign on to legislation that would amend the issue, by rescheduling or descheduling cannabis. In fact, Durbin has only cosponsored two marijuana-focused bills over the course of his 36 years in Congress to date.

One would have required the DEA to conduct clinical trials on cannabidiol (CBD) and later determine whether the compound should be a controlled substance. The other would have allowed defendants in federal court cases to introduce evidence showing that any marijuana activity was in compliance with a state medical cannabis law.

Notably, during his time in the House, Durbin cosponsored the Anti-Drug Abuse Act of 1986, which included provisions that expanded the criminalization of drugs as well as a section tied to the problem he complained about at Tuesday’s hearing. That provision amended the CSA “to provide that controlled substance analogues shall be treated as a schedule I substance.”

“I appreciate Senator Durbin’s comments about limiting federal research,” Don Murphy, director of federal policies for the Marijuana Policy Project, told Marijuana Moment. “I’d feel even better about it if he channeled that energy and interest by putting his name on legislation to fix the problem”

Congressional Funding Bill Protects Cannabis Banking And Lets DC Legalize Marijuana Sales

Photo courtesy of Senate Judiciary Committee.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Politics

Congress Votes To Block Feds From Enforcing Marijuana Laws In Legal States

Published

on

The House of Representatives approved a far-reaching measure on Thursday to prevent the Department of Justice from interfering with state marijuana laws, including those allowing recreational use, cultivation and sales.

The amendment, which also shields cannabis laws in Washington, D.C. and U.S. territories, is now attached to a large-scale appropriations bill to fund parts of the federal government for Fiscal Year 2020.

Please visit Forbes to read the rest of this piece.

(Marijuana Moment’s editor provides some content to Forbes via a temporary exclusive publishing license arrangement.)

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Watch Live: Congressional Committee Discusses Medical Marijuana And Military Veterans

Published

on

A congressional committee held a hearing on four bills that concern veterans and medical marijuana on Thursday.

The House Veterans’ Affairs Committee discussed one piece of legislation that would allow doctors at the U.S. Department of Veterans Affairs (VA) to issue medical cannabis recommendations in states where it’s legal. That bill was introduced by Rep. Earl Blumenauer (D-OR).

The panel also took up a bill sponsored by Rep. Lou Correa (D-CA) that would require VA to conduct clinical trials on the therapeutic potential of cannabis in the treatment of conditions such as post-traumatic stress disorder and chronic pain.

“The men and women that I meet back home vouch for the therapeutic benefits of medical cannabis and support further research into the issue,” Correa said in testimony prepared for the hearing. “The legislation provides a framework for that research to ensure a scientifically-sound study on the issue.”

“Cannabis must be objectively researched. Period,” Rep. Mark Takano (D-CA), chair of the committee, said in support of the legislation. “Medicinal cannabis may have the potential to manage chronic pain better than opioids and treat PTSD.”

Rep. Phil Roe (R-TN), ranking member on the committee, agreed that VA should be studying the therapeutic potential of cannabis for veterans but complained that the proposed bill is excessively prescriptive. The congressman, who introduced a similar piece of legislation in January, said lawmakers shouldn’t “be telling the scientists how to design their studies.”

Other legislation that came up for consideration was a bill from Rep. Seth Moulton (D-MA), a 2020 presidential candidate, that would provide training on medical cannabis for VA health practitioners.

Finally, the committee heard testimony on another Moulton proposal that would require VA to conduct a survey to “measure cannabis use by veterans.”

Watch the hearing below:

Witnesses who testified before the committee include Adrian Atizado, deputy national legislative director of Disabled American Veterans (DAV), Travis Horr, director of government affairs with Iraq and Afghanistan Veterans of America (IAVA) and Carlos Fuentes, director of national legislative service for Veterans of Foreign Wars (VFW).

The VFW representative said the organization supports all but one of the cannabis bills. While the group agrees with the intent of allowing VA doctors to recommend cannabis, it “believe it is unacceptable for VA providers to recommend a treatment that they are unable to provide veterans and force patients to pay for the full cost of such care.”

DAV voiced support for legislation requiring VA to study medical cannabis and also to survey veterans on their marijuana usage.

And IAVA came out in strong support for the research bill. In testimony, the group said that “without research done by VA surrounding cannabis, veterans will not have conclusive answers to ways cannabis might aide their health needs. This is unacceptable.”

“VA houses some of the most innovative and best-in-class research this country has to offer. It should not be shutting its doors on a potentially effective treatment option because of politics and stigma,” the group said. “Our nation’s veterans deserve better.”

Larry Mole, chief consultant of population health services at the federal Veterans Health Administration, testified that VA opposes all four of the cannabis bills.

He expressed concerns that VA doctors would be penalized if they recommend medical cannabis, that the research requirement would be excessively onerous and that VA is already studying marijuana, that VA doctors already have access to training materials on the subject and that the proposed anonymous survey would require veterans to disclose information that could make them identifiable.

“The legislation would prescriptively define how the surveys would be conducted, but it does not provide the purpose, goals, or objectives for the surveys,” he said. “We have significant concerns that veterans will not want to participate, despite the survey being anonymous.”

Several committee members pressed Mole on VA’s current research efforts, noting the widespread support among veterans to study the medicinal benefits of marijuana.

Rep. Mike Levin (D-CA) said that he meets with veteran constituents each week and asked the VA representative, “[w]hat am I to tell them when they ask when is this [research] actually going to happen?”

“When is this research going to occur? When is the VA going to listen to the 92 percent of veterans across all political stripes and ideologies that want to see this done?” he said.

Mole pointed to the single ongoing VA clinical trial that just recently recruited its first participant focusing on the benefits of CBD for post-traumatic stress disorder. He encouraged Levin to tell his constituents to look up the study and apply to participate if they were interested.

Rep. Andy Barr (R-KY) characterized the VA’s study as “a baby steps approach” to the issue given that CBD alone isn’t representative of the products that veterans are using in the commercial market.

After the House Veterans’ Affairs Subcommittee on Health held a hearing on several of the cannabis proposals in April, the full committee was set to vote on two marijuana measures last month. That hearing was cancelled, however.

Blumenauer is also pursuing cannabis reform for veterans through a different vehicle: an appropriations bill that’s being debated on the House floor this and next week. He introduced an amendment that would prohibit VA from “interfering with a veteran’s participation in a state medical cannabis program, denying a veteran who participates in a state medical cannabis program from being denied VA services, and interfering with the ability of VA health care providers to recommend participation in state medical cannabis programs.”

This was the second congressional committee hearing on marijuana-related issues this week. On Wednesday, the House Small Business Committee met to discuss challenges and opportunities for entrepreneurs in the emerging cannabis industry.

This story has been updated to include additional testimony from witnesses.

House Passes Amendments Stripping DEA Funding And Pushing FDA To Regulate CBD

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

House Passes Amendments Stripping DEA Funding And Pushing FDA To Regulate CBD

Published

on

Two drug policy amendments cleared the House of Representatives on Thursday, building on reform victories in the chamber the day before.

One measure addresses funding for the Drug Enforcement Administration (DEA) and the other would direct the Food and Drug Administration (FDA) to establish regulations for adding CBD to foods and dietary supplements.

The first amendment, introduced by Rep. Alexandria Ocasio-Cortez (D-NY), would transfer $5 million from the DEA to an opioid treatment program. It passed without opposition on a voice vote and is now be attached to the House version of a large-scale spending bill, but it remains to be seen how the Senate will set funding levels for the agency in its own version of the funding legislation.

“I offer this amendment because ending the war on drugs has to mean changing our priorities in order to keep all communities safe and healthy,” Ocasio-Cortez said. “The best way we do that is by offering people the help and support they need before arrest and criminalization should be considered in the first place.”

She added that the DEA is still receiving $2.36 billion in funding, which is $90 million higher than was appropriated for the last fiscal year. It’s also about $78 million higher than President Trump requested in his budget.

Rep. Jose Serrano (D-NY), the chairman of an appropriations subcommittee that handles Justice Department funding, rose in support of the amendment, stating that opioids “are a serious threat to the health and wellbeing of our communities, and we must do everything we can to combat this epidemic.”

Michael Collins, director of national affairs for the Drug Policy Alliance, told Marijuana Moment that the successful vote “should send a message to the DEA—it’s not business as usual anymore.”

“We want to end the drug war and we will fight for it. We will drain you dollar-by-dollar, cent-by-cent, if that’s what it takes,” he said.

Rep. Robert Aderholt (R-AL) claimed time designated for the opposition on the floor but said he supports the amendment. The congressman did note, however, that funding for opioid abuse prevention grants has increased by 360 percent since 2017 and that “we want to work with both sides to make sure we have the appropriate funds necessary to make sure we fight this opioid addiction that has taken over so many parts of the country.”

In closing, Ocasio-Cortez said “just as the epidemic is exploding so should our commitment to address this problem.”

“We have overfunded one agency and we should move that to make sure that we are getting people the care they need,” she said.

Dan Riffle, senior counsel and policy advisor in Ocasio-Cortez’s office told Marijuana Moment that the amendment is “a good start, but it’s not enough.”

“Every dollar we waste trying and failing to reduce supply is a dollar that should be spent on treatment and demand reduction,” he said.

This is the second drug policy amendment the freshman congresswoman has introduced that’s been brought to the House floor. However, her earlier proposal, which was meant to lift barriers to research for psychedelic substances such as psilocybin and MDMA, was rejected when it came up for a vote as part of separate appropriations legislation last week.

The FDA amendment, introduced by Rep. Jerry McNerney (D-CA), was approved as part of an en bloc voice vote combining other relatively noncontroversial measures and it did not receive debate on the floor. The measure aims to resolve a problem that the FDA has repeatedly raised since hemp and its derivatives were federally legalized under the 2018 Farm Bill.

Because CBD exists as an FDA-approved drug and has never been allowed in the food supply before, the agency’s former commissioner said Congress may have to pass separate legislation to provide for its lawful marketing.

The amendment’s description directs FDA to “undertake a process to make lawful a safe level for conventional foods and dietary supplements containing cannabidiol (CBD) so long as the products are compliant with all other FDA rules and regulations.”

Two other drug policy amendments were debated in the chamber on Wednesday. A measure that would block the Justice Department from using its funds to intervene in state marijuana laws was approved on a voice vote but still needs to pass in a recorded vote; another that extends similar protections to tribal cannabis programs passed without a request for a recorded vote.

Congress Clashes On Marijuana Amendments In Floor Debate

This story was updated to include comment from Riffle.

Photo courtesy of Philip Steffan.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Stay Up To The Moment

Marijuana News In Your Inbox


Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!